Exceptional results in neuroendocrine-metastases-caused paraplegia treated with [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC), a radiolabelled somatostatin analogue.
The case history is presented of a patient with paraplegia caused by progressive spinal cord compression due to bone metastases of a neuroendocrine pulmonary tumour. After failed external radiotherapy, the patient received targeted internal radiotherapy administered as a fractionated treatment with intravenous injections of a total of 7400 MBq/m2 of [90YDOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC), a radiolabelled somatostatin analogue. This case history highlights the value of 90Y-DOTATOC in the treatment of neuroendocrine tumours and the importance and possibility of good palliation of neuroendocrine bone metastases.
Waldherr
C
C
Clinical Nuclear Medicine, University Hospital, School of Medicine, Basel, Switzerland. nukmedass@uhbs.ch
Haldemann
A
A
Maecke
H R
HR
Crazzolara
A
A
Mueller-Brand
J
J
D006801:Humans; D008175:Lung Neoplasms / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D018358:Neuroendocrine Tumors / Q000150:complications / Q000473:pathology / Q000532:radiotherapy* / Q000556:secondary; D015282:Octreotide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010264:Paraplegia / Q000209:etiology* / Q000517:prevention & control; D019275:Radiopharmaceuticals / Q000627:therapeutic use*; D013004:Somatostatin / Q000031:analogs & derivatives*; D013117:Spinal Cord Compression / Q000209:etiology* / Q000532:radiotherapy; D013125:Spinal Neoplasms / Q000150:complications / Q000473:pathology / Q000532:radiotherapy* / Q000556:secondary; D013904:Thoracic Vertebrae; D015021:Yttrium Radioisotopes / Q000627:therapeutic use
D019275:Radiopharmaceuticals; D015021:Yttrium Radioisotopes; D013004:Somatostatin; D015282:Octreotide; C106246:Edotreotide